Rationale: Cyclic nucleotide phosphodiesterases (PDEs) through the degradation of cGMP play critical roles in maintaining cardiomyocyte homeostasis. Ca 2؉ /calmodulin (CaM)-activated cGMP-hydrolyzing PDE1 family may play a pivotal role in balancing intracellular Ca 2؉ /CaM and cGMP signaling; however, its function in cardiomyocytes is unknown. Objective: Herein, we investigate the role of Ca 2؉ /CaM-stimulated PDE1 in regulating pathological cardiomyocyte hypertrophy in neonatal and adult rat ventricular myocytes and in the heart in vivo. Methods and Results: Inhibition of PDE1 activity using a PDE1-selective inhibitor, IC86340, or downregulation of PDE1A using siRNA prevented phenylephrine induced pathological myocyte hypertrophy and hypertrophic marker expression in neonatal and adult rat ventricular myocytes. Importantly, administration of the PDE1 inhibitor IC86340 attenuated cardiac hypertrophy induced by chronic isoproterenol infusion in vivo. Both PDE1A and PDE1C mRNA and protein were detected in human hearts; however, PDE1A expression was conserved in rodent hearts. Moreover, PDE1A expression was significantly upregulated in vivo in the heart and myocytes from various pathological hypertrophy animal models and in vitro in isolated neonatal and adult rat ventricular myocytes treated with neurohumoral stimuli such as angiotensin II (Ang II) and isoproterenol. Key Words: phosphodiesterase Ⅲ cGMP Ⅲ cardiomyocyte Ⅲ cardiac hypertrophy C a 2ϩ /calmodulin (CaM)-dependent signaling has been implicated in promoting pathological gene expression involved in hypertrophy and heart failure through the activation of Ca 2ϩ /CaM-dependent kinases, phosphatases, and ion channels. 1 Recently, a number of intrinsic negative regulators of cardiac growth have been identified which activate cGMPdependent signaling. 2 Stimulation of cGMP synthesis through genetic upregulation of natriuretic peptide receptor (guanylyl cyclase-A) prevents neurohumoral or pressure overload induced hypertrophy, 3 whereas disruption of cGMP synthesis results in enhanced hypertrophy and deteriorated cardiac function. 4 Likewise, chronic inhibition of cGMP metabolism by a cyclic nucleotide phosphodiesterase (PDE)5 inhibitor prevents and reverses pressure overload induced cardiac hypertrophy. 5 PDEs, by degrading cAMP and/or cGMP, regulate the amplitude, duration, and compartmentation of intracellular cyclic nucleotide signaling. PDEs constitute a superfamily of enzymes grouped into 11 broad families based on their distinct kinetic, regulatory, and inhibitory properties. PDE family members are also differentially expressed in various tissues and present within distinct subcellular domains. Together, these properties enable PDE enzymes to regulate the spatiotemporal, intracellular cAMP and cGMP gradients in response to various external stimuli. At least 5 PDE families, PDE1 to -5, have been reported in the heart, of which PDE1 and PDE5 are most likely responsible for cGMP hydrolysis. Logically, alteration of cGMP-hydrolyzing PDE expression/ activity may contribute to a pathological imbalance observed during prolonged stress. Ca 2ϩ /CaM-stimulated PDE1 family constitutes 3 gene products: PDE1A, PDE1B, and PDE1C. 6 In vitro, PDE1A and PDE1B have been shown to preferentially hydrolyze cGMP with greater affinity than cAMP, whereas PDE1C hydrolyzes cAMP and cGMP with equally high affinity. 6 In vivo, PDE1A has been shown to preferentially hydrolyze cGMP in vascular smooth muscle cells. 7,8 Although a recent study has reported that PDE1C is highly expressed in the human myocardium and present in human cardiomyocytes, 9 the physiological and pathological roles of PDE1 in the heart are still unknown. Here, we identified both PDE1A and PDE1C expression in human hearts, whereas PDE1A expression was more conserved in rodent hearts and in neonatal rat ventricular myocytes (NRVMs) and adult rat ventricular myocytes (ARVMs). Using various loss-of-function strategies in isolated NRVMs and ARVMs, we demonstrated that PDE1A regulates cardiomyocyte hypertrophy, which is dependent on modulating cGMP/PKG (cGMP-dependent protein kinase) signaling. We further showed that the PDE1-selective inhibitor IC86340 was able to reduce myocyte hypertrophy in an isoproterenol (ISO)-induced hypertrophy mouse model. Moreover, we observed that PDE1A expression was significantly upregulated in the heart and myocytes from various pathological hypertrophy rodent models and in isolated cardiomyocytes treated with hypertrophic stimuli. Together, our findings suggest a novel role for PDE1, particularly PDE1A, in regulating cardiomyocyte hypertrophic growth.
C a 2ϩ /calmodulin (CaM)-dependent signaling has been implicated in promoting pathological gene expression involved in hypertrophy and heart failure through the activation of Ca 2ϩ /CaM-dependent kinases, phosphatases, and ion channels. 1 Recently, a number of intrinsic negative regulators of cardiac growth have been identified which activate cGMPdependent signaling. 2 Stimulation of cGMP synthesis through genetic upregulation of natriuretic peptide receptor (guanylyl cyclase-A) prevents neurohumoral or pressure overload induced hypertrophy, 3 whereas disruption of cGMP synthesis results in enhanced hypertrophy and deteriorated cardiac function. 4 Likewise, chronic inhibition of cGMP metabolism by a cyclic nucleotide phosphodiesterase (PDE)5 inhibitor prevents and reverses pressure overload induced cardiac hypertrophy. 5 PDEs, by degrading cAMP and/or cGMP, regulate the amplitude, duration, and compartmentation of intracellular cyclic nucleotide signaling. PDEs constitute a superfamily of enzymes grouped into 11 broad families based on their distinct kinetic, regulatory, and inhibitory properties. PDE family members are also differentially expressed in various tissues and present within distinct subcellular domains. Together, these properties enable PDE enzymes to regulate the spatiotemporal, intracellular cAMP and cGMP gradients in response to various external stimuli. At least 5 PDE families, PDE1 to -5, have been reported in the heart, of which PDE1 and PDE5 are most likely responsible for cGMP hydrolysis. Logically, alteration of cGMP-hydrolyzing PDE expression/ activity may contribute to a pathological imbalance observed during prolonged stress. Ca 2ϩ /CaM-stimulated PDE1 family constitutes 3 gene products: PDE1A, PDE1B, and PDE1C. 6 In vitro, PDE1A and PDE1B have been shown to preferentially hydrolyze cGMP with greater affinity than cAMP, whereas PDE1C hydrolyzes cAMP and cGMP with equally high affinity. 6 In vivo, PDE1A has been shown to preferentially hydrolyze cGMP in vascular smooth muscle cells. 7, 8 Although a recent study has reported that PDE1C is highly expressed in the human myocardium and present in human cardiomyocytes, 9 the physiological and pathological roles of PDE1 in the heart are still unknown. Here, we identified both PDE1A and PDE1C expression in human hearts, whereas PDE1A expression was more conserved in rodent hearts and in neonatal rat ventricular myocytes (NRVMs) and adult rat ventricular myocytes (ARVMs). Using various loss-of-function strategies in isolated NRVMs and ARVMs, we demonstrated that PDE1A regulates cardiomyocyte hypertrophy, which is dependent on modulating cGMP/PKG (cGMP-dependent protein kinase) signaling. We further showed that the PDE1-selective inhibitor IC86340 was able to reduce myocyte hypertrophy in an isoproterenol (ISO)-induced hypertrophy mouse model. Moreover, we observed that PDE1A expression was significantly upregulated in the heart and myocytes from various pathological hypertrophy rodent models and in isolated cardiomyocytes treated with hypertrophic stimuli. Together, our findings suggest a novel role for PDE1, particularly PDE1A, in regulating cardiomyocyte hypertrophic growth.
Methods
Animal care and use was in accordance with institutional guidelines. Cardiac hypertrophy was induced in vivo by chronic infusion of angiotensin II (Ang II) at 0.7 mg/kg per day for 2 weeks in Sprague-Dawley rats or ISO at 30 mg/kg per day for 1 week in C57Bl/6J mice, as previously described. 10 Thoracic aortic constriction (TAC) was performed in 8-to 10-week-old male C57Bl/6J mice as previously described. 10, 11 IC86340 (3 mg/kg per day) or vehicle was administered daily via IP injection.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

PDE1 Inhibitors Reduce Cardiomyocyte Hypertrophy and Hypertrophic Gene Expression in Cardiomyocytes
To determine the role of PDE1 in cardiomyocyte hypertrophy, we first used pharmacological inhibitors of PDE1 in isolated NRVMs. Treatment of NRVMs with the PDE1 inhibitor IC86340 8 dose-dependently attenuated the phenylephrine (PE)-induced protein synthesis, as assessed by leucine incorporation ( Figure 1A) . A distinct PDE1 inhibitor, 8-MM-IBMX (8-methoxymethyl-isobutylmethylxanthine), 12 used at 20 mol/L, elicited similar inhibitory effects (data not shown). Furthermore, IC86340 treatment resulted in a substantial reduction in the PE-induced myocyte surface area ( Figure 1B) . Similarly, we observed that IC86340 also blunted ISO-stimulated protein synthesis (data not shown). Based on previously reported IC 50 values of IC86340 on inhibiting different PDE family members (Online Table I ), the doses of IC86340 used in this study should preferentially hydrolyze PDE1.
The antihypertrophic effects of PDE1 inhibitor correlated with a reduction in the mRNA levels of hypertrophic markers, such as atrial natriuretic peptide (ANP) and brain natriuretic peptide ( Figure 1C and 1D) . Moreover, we examined ANP expression via perinuclear ANP immunostaining as described previously 13 ( Figure 1E and 1F) . We found that PE markedly stimulated the percentage of ANP/actinin-positive cells compared to the vehicle control, whereas IC86340 treatment abrogated these effects. Together, these results implicate PDE1 in regulating pathological myocyte hypertrophy in vitro.
PDE1 Inhibitor Prevents Adult Rat Ventricular Myocyte Hypertrophy
We next examined the effects of PDE1 inhibition on ARVM hypertrophy by measuring myocyte surface area, width/ length of myocytes, and protein synthesis. Indeed, PDE1 inhibition with IC86340 in ARVMs significantly reduced the PE-induced myocyte surface area (Figure 2A and 2B), myocyte width ( Figure 2C ), and protein synthesis assessed by [ 3 H]-leucine incorporation ( Figure 2D ).
PDE1 Inhibitor Reduced Myocyte Hypertrophy In Vivo in ISO-Induced Mouse Hypertrophy Model
To further examine whether PDE1 inhibition attenuates adult cardiac hypertrophy in vivo, we administered the PDE1 inhibitor IC86340 in mice. We found that mice receiving daily IC86340 treatment at the doses of 3 and 6 mg/kg per day had normal heart and body weights. A small reduction of blood pressure Ϸ10 to 20 mm Hg and no changes in heart rate were observed (Online Figure I) , which is consistent with previous findings that PDE1 regulates vascular reactivity. 7, 14 Therein, we examined the effects of IC86340 on cardiac hypertrophy using a mouse hypertrophy model induced by ISO infusion at 30 mg/kg per day for 7 days. It has been demonstrated that there is no correlation between ISOinduced cardiac hypertrophy and blood pressure. 15 We found that ISO infusion significantly induced cardiac hypertrophy analyzed by gross heart morphology ( Figure 3A) , heart weight/body weight ratio ( Figure 3B ), and heart weight/tibia length ratio ( Figure 3C ), which were attenuated by IC86340 treatment (3 mg/kg per day). Furthermore, we found that ISO enlarged cardiac myocyte cross-sectional area and elevated ANP gene expression, which is significantly reduced by IC86340 treatment (Figure 3D through 3F ). We determined the plasma level of IC86340 by PDE assay to be approximately 12 mol/L (Online Data Supplement). Taken together, these results support the notion that PDE1 plays a critical role in ISO-induced cardiac hypertrophy in vivo.
PDE1A, -1B, and -1C Are Differentially Expressed in Adult Human, Rat, and Mouse Hearts, As Well As in NRVMs and ARVMs
To evaluate the presence of Ca 2ϩ /CaM-stimulated PDE1 enzymes in the heart and in isolated cardiomyocytes, both mRNA and protein expression were examined in heart samples from various species relative to known PDE1-expressing tissues such as brain and testis. We observed PDE1A mRNA to be detected at nearly equivalent levels in human, rat, and mouse hearts, whereas PDE1C was primarily detected in human and mouse hearts, and PDE1B was weakly detected overall in the heart (Figure 4A through 4C). We observed that PDE1A protein levels were comparable in hearts from different species, whereas PDE1B was not detectable in the hearts, consistent with the mRNA expression ( Figure 4D ). However, mouse heart elicited much lower PDE1C protein expression compared with human, inconsistent with the mRNA expression level ( Figure 4D ). The lower PDE1C protein in mouse heart is unlikely attributable to antibody insensitivity because the antibody strongly recognized mouse testis ( Figure 4D ). Additionally, we observed PDE1A mRNA and protein in both NRVMs and ARVMs at comparable levels to that in adult rat heart, whereas PDE1B and PDE1C expression levels were significantly lower in these cells ( Figure 4E and 4F) . Together, these data indicate that both PDE1A and PDE1C isoforms are present in human hearts, whereas PDE1A expression is conserved in rodent hearts, particularly in rat cardiomyocytes.
Downregulation of PDE1A Expression Inhibits Cardiomyocyte Hypertrophy in NRVMs and ARVMs
To specifically determine the contribution of PDE1A in myocyte hypertrophy, we used gene silencing to downregulate PDE1A expression. PDE1A expression levels were significantly downregulated in NRVMs by a PDE1A siRNA specifically targeting the N-terminal sequence of rat PDE1A ( Figure 5A , inset). The negative control, a nontargeting control siRNA, had no effect on PDE1A protein levels. As a specificity control, we found that PDE1A siRNA did not alter the expression of other PDE isoforms such as PDE1C and PDE5A (data not shown). We found that treatment with PDE1A siRNA significantly abrogated the PE-mediated increase in protein synthesis ( Figure 5A ) and total myocyte surface area compared to controls in NRVMs ( Figure 5B ). We obtained similar results in NRVMs treated with adenovirus (Ad) encoding a different PDE1A short hairpin (sh)RNA, specifically targeting the C-terminal sequence of rat PDE1A (Online Figure II) . These findings coincided with reduced ANP marker expression in NRVMs ( Figure 5C ). Downregulation of PDE1A followed by IC86340 treatment reduced NRVM protein synthesis to similar levels, whereas the PDE5 inhibitor sildenafil potentiated these effects, suggesting that IC86340 effects are attributed to PDE1A ( Figure  5D ). Adenovirus (Ad)-PDE1A shRNA also significantly downregulated PDE1A expression in ARVMs ( Figure 5E , inset), in which we observed blunted PE-induced protein synthesis ( Figure 5E ) and total myocyte area ( Figure 5F ).
Despite the relatively low PDE1C expression level in NRVMs, lower PDE1C could be functionally relevant in rat myocytes. Therefore, we also examined the effect of PDE1C siRNA in PE-stimulated myocyte hypertrophy. We found that downregulation of PDE1C expression via siRNA did not attenuate PE-stimulated cardiomyocyte hypertrophy (Online Figure III) or ANP gene expression (Online Figure IV) . These results suggest that PDE1A but not PDE1C specifically regulates PE-stimulated hypertrophic growth.
PDE1A Expression Is Upregulated With Hypertrophic Stimulation In Vivo and in Isolated Cardiomyocytes In Vitro
To further assess the pathophysiological role of PDE1A in the heart, we measured PDE1A expression levels in the ventricle during pathological cardiac hypertrophy in vivo. Interestingly, we observed an approximate 2-fold increase in PDE1A mRNA levels ( Figure 6A ) and a 2.5-fold increase in PDE1A protein levels ( Figure 6B ) in mouse hearts with ISO infusion (30 mg/kg per day) for 7 days relative to the vehicle control group. We also found significant upregulation of PDE1A protein levels in mouse hearts after chronic pressure overload via TAC for 3 weeks ( Figure 6C ) and in rat hearts subjected to chronic Ang II infusion (0.7 mg/kg per day) for 2 weeks ( Figure 6D ).
To determine whether the PDE1A induction occurs in cardiomyocytes in vivo, we performed immunohistochemical analyses of PDE1A in heart sections from control and hypertrophic rodent hearts. As shown in Figure 7A , we found that PDE1A staining is significantly increased in the myocardium of hypertrophic hearts induced by TAC compared with sham controls. Obviously, the increase of PDE1A was detected in cardiomyocytes, although it may not be exclusive ( Figure 7A, right) . We obtained very similar observations in To further determine whether this PDE1A induction occurs in isolated NRVMs and ARVMs, we found that in NRVMs, ISO treatment for up to 48 hours increased PDE1A protein levels relative to control ( Figure 7D ). Similarly, we observed ISO or Ang II treatment of ARVMs for 24 hours resulted in increased PDE1A protein levels ( Figure 7E ). Together, these data suggest that PDE1A expression can be upregulated in cardiomyocytes via hypertrophic stimuli both in vivo and in vitro.
The Antihypertrophic Effect of PDE1A Is Mediated by a cGMP/PKG-Dependent Mechanism
Intracellular cGMP levels were significantly decreased in PE-stimulated NRVMs, which was prevented by the PDE1 inhibitor IC86340 or PDE1A shRNA ( Figure 8A and 8B). However, the cAMP levels were increased with PE treatment and IC86340 did not significantly alter the cAMP levels (Online Figure VI, A) . We next assessed cGMP-activated PKG and cAMP-dependent protein kinase (PKA) activation. We found that PKG activity is decreased with PE stimulation, and IC86340 or PDE1A shRNA treatment diminished PE effects and enhanced PKG activity ( Figure 8C ), which was consistent with cGMP changes. PKA activity, however, was not significantly altered by PDE1 inhibition (Online Figure  VI, B) .
We then investigated the involvement of PKG-1. Inhibition of PKG activity by either Rp-8-Br-PET-cGMPs or the peptide inhibitor DT-2 significantly blocked the inhibitory effect of IC86340 on [
3 H]-leucine incorporation ( Figure 8E ). To further confirm the specific involvement of PKG-1, we downregulated PKG-1 expression using Ad-PKG-1 shRNA ( Figure 8F , inset). We found that PKG-1 shRNA abolished the effects of IC86340 on myocyte hypertrophy ( Figure 8F ), similar to the effects of PKG inhibitors. We also examined the role of PKA using an adenovirus expressing the PKA inhibitor. We found that PKA inhibition via PKA inhibitor reduced PE-stimulated myocyte hypertrophy (Online Figure  VII , C), consistent with previous findings that PKA activation is prohypertrophic. 16 Importantly, when PKA was inhibited by PKA inhibitor, IC86340 still reduced myocyte hypertrophy (Online Figure VI, C). These results suggest that the antihypertrophic effects of PDE1 inhibition is mediated through PKG-1 but not PKA activation.
Discussion
Previous studies have demonstrated that intracellular Ca 2ϩ / CaM-dependent signaling promotes maladaptive hypertrophic gene expression in cardiomyocytes through various effectors such as the protein phosphatase calcineurin, Ca 2ϩ / CaM-dependent kinase II, and transcription factors myocyte enhancer factor 2 and NFAT (nuclear factor of activated T-cells). 17 Endogenous cGMP-dependent signaling is able to negatively regulate cardiac hypertrophy both in vitro and in vivo, by suppressing G q/11 activation and normalizing Ca 2ϩ signaling. 5, 18 The present study identifies a novel function of Ca 2ϩ /CaM-dependent PDE1 in regulating pathological cardiomyocyte hypertrophy. Given that PDE1 is a Ca 2ϩ /CaM stimulated PDE capable of hydrolyzing cGMP, we hypothesized that PDE1 may play a pivotal role in the crosstalk of Ca 2ϩ and cGMP signaling to promote cardiac growth. We demonstrated that inhibition of PDE1 activity, particular PDE1A, blocked PE-or ISO-induced attenuation of cGMP/ PKG signaling and cardiomyocyte hypertrophy in vitro. Administration of the PDE1 inhibitor IC86340 also significantly reduced cardiac hypertrophy in a mouse hypertrophy model in vivo. Moreover, PDE1A expression was significantly upregulated in the heart and myocytes from various pathological hypertrophy animal models in vivo and in isolated NRVMs and ARVMs treated with neurohumoral showing PDE1A, PDE1B, and PDE1C mRNA expression in adult human, rat, and mouse heart tissue compared to indicated-controls (mouse brain for PDE1A and 1B or mouse testis for PDE1C). RT-PCR data were quantified by densitometry in a linear range from 3 independent samples, which were normalized to GAPDH mRNA levels and expressed relative to human hearts. AU indicates arbitrary units. D, Representative Western blot showing relative PDE1A, PDE1B, and PDE1C protein levels in human, rat, and mouse hearts, compared to respective controls (brain for PDE1A and PDE1B; testis for PDE1C). GAPDH was used to normalize protein loading. E and F, PDE1 expression in isolated neonatal and adult cardiomyocytes (NRVMs and ARVMs). RT-PCR showing relative PDE1A, -1B, and -1C mRNA levels in NRVMs, ARVMs, and rat hearts, compared to respective controls (E). Western blot depicting relative PDE1A, -1B, and -1C protein levels in NRVMs and ARVMs, compared to rat hearts and respective controls. GAPDH was used to normalize mRNA and protein expression.
stimuli in vitro. Together, these findings suggest that Ca 2ϩ , by activating PDE1A, decreases cGMP levels and PKG activity and thus leads to potentiated cardiomyocyte hypertrophy. Upregulation of PDE1A expression on neurohumoral or biomechanical stress during cardiac hypertrophy further enhances PDE1A activity and attenuates cGMP/PKG signaling (proposed model in Online Figure IX) . The PDE1 family is comprised of Ca 2ϩ /CaM-stimulated PDEs, including PDE1A, -1B, and -1C. It was previously shown that Ca 2ϩ /CaM-stimulated PDE1 represents the majority of the cGMP-hydrolyzing PDE activity in the human myocardium; however, this study did not identify the cardiac cell type or the PDE1 isoform responsible for this activity. 19 An early report by Bode et al supposed that Ca 2ϩ /CaMstimulated PDE1 activity was absent from isolated ARVMs and restricted to the nonmyocyte fraction of the whole rat ventricle. 20 PDE1A mRNA expression and/or activity has been described in cardiac tissue from several species including human, 21 bovine, 22 canine, 23 and rat. 24 Because most of these studies used whole heart lysates, it is still unclear whether these isoforms are attributed to cardiomyocytes or other cardiac cell types. More recently, it has been shown that PDE1C is expressed in cardiomyocytes of the human myocardium, whereas PDE1A protein was not detected in these human heart samples. 9 Herein, we identified both PDE1A and PDE1C protein and mRNA in human hearts (Figure 4) , with PDE1A expression conserved in rat and mouse hearts. In fact, a previous study using immunoprecipitation and PDE assay demonstrated that PDE1A and PDE1C represent approximately 80% and 20% of total PDE1 activity in the rat heart, respectively. 25 The inconsistencies of PDE1A expression with previous reports may be rationalized by differences in tissue sample preparation or antibody cross-reactivity. Likewise, the discrepancy between PDE1C mRNA and protein level in mouse heart should be further characterized. To address the specific contribution of PDE1A and PDE1C in mediating the effects of selective PDE1 inhibition on cardiomyocyte hypertrophy, we used siRNA specifically targeting PDE1A and PDE1C in NRVMs ( Figure 5 and Online Figure III) . These data support a critical role for PDE1A but not PDE1C in mediating the antihypertrophic effect of PDE1 inhibition in NRVMs. The negligible effect of PDE1C downregulation on myocyte hypertrophy may be attributable to the lower expression level of PDE1C (Online Figure III) or may suggest an alternative role of PDE1C in rat myocytes. In fact, studies from cells highly expressing endogenous PDE1C elicited increased intracellular cAMP on inhibition of PDE1C, 26, 27 suggesting that PDE1C is able to regulate cAMP signaling. However, specific downregulation of PDE1A primarily elevated cGMP levels in both vascular smooth muscle cells 8 and cardiomyocytes (Figure 8 and Online Figure VI) , suggesting PDE1A and PDE1C play distinct roles in intracellular cyclic nucleotide signaling. Our data that IC86340 prevents adverse cardiac hypertrophy in a mouse ISO infusion model suggest an important role for PDE1A in regulating cardiac hypertrophy; however, we cannot entirely rule out the contribution of PDE1C in mouse heart. Generation of PDE1A-and PDE1C-deficient animal models will be indispensable to further examine their respective roles in adult cardiomyocyte function in vivo, which is currently under investigation.
PDE5 is another cGMP-hydrolyzing PDE expressed in cardiac tissues. Earlier reports demonstrated a low level of expression of PDE5 in hearts from various species and isolated cardiomyocytes. 19 Nonetheless, a recent study using PDE5A shRNA in isolated cardiomyocytes demonstrated an important role for PDE5A in these cells, 28 which may contribute to the cardioprotective effects elicited by sildenafil in preventing adverse cardiac remodeling and dysfunction from pressure overload. 5 PDE5 and PDE1 enzymes are likely coupled to distinct intracellular cGMP-dependent pathways and regulatory mechanisms. For example, PDE5 activity is primarily stimulated on NO induced cGMP/PKG activation, which leads to a rapid decline in intracellular cGMP. Thus, PDE5 plays an important role in the negative feedback regulation of NO/cGMP signaling. However, PDE1 activity is stimulated by Ca 2ϩ -elevating stimuli (ie, Ang II, ET-1, and ␣-AR agonists), and PDE1-dependent cGMP hydrolyzing activity is predominant during elevations in [Ca 2ϩ ] i 29 In fact, we have observed that the effects of PDE1 inhibitor on cGMP elevation were Ca 2ϩ /CaM-dependent (Online Figure VII) . Thus PDE1 plays a critical role in the Ca 2ϩ -mediated negative regulation of cGMP signaling. 30 However, the source of the Ca 2ϩ to which PDE1 alters cGMP-dependent signaling is still not clear and is currently under investigation. We also determined the additive or redundant effects of PDE1 and PDE5 on cardiomyocyte hypertrophy. We found that both IC86340 and PDE5 inhibitor sildenafil individually attenuated PE-induced NRVM hypertrophy, whereas the combination of PDE inhibitors potentiated these effects (Online Figure VIII) . Moreover, we found that the inhibitory effect of PDE1A shRNA on cardiomyocyte hypertrophy could be potentiated by sildenafil but not IC86340 ( Figure  5D ). These findings, together, suggest that PDE1A and PDE5A are likely coupled to unique cGMP pools and PDE1A may regulate specific cGMP pools with elevations of [Ca 2ϩ ] i during hypertrophic stimulation. PKG appears to be a critical mediator for the antihypertrophic effects resulted from both PDE1 ( Figure 8 ) and PDE5 inhibition. 31 However, the role and mechanism of PKG in cardiac hypertrophy in vivo deserves further investigation. In summary, the present findings elucidate a novel role of PDE1, particularly PDE1A in regulating cardiomyocyte hypertrophy and myocardial remodeling during cardiac disease.
1
Supplemental Materials and Methods
Reagents, antibodies, and adenoviruses. IC86340 was provided by ICOS Corporation. Sildenafil was prepared from drug tablet obtained from pharmacy (tablets were dissolved in sterile water and filtered). 8-MM-IBMX and BAPTA-AM were purchased from Biomol, while PKG inhibitors, Rp-8-Br-PET-cGMPS and DT-2 were purchased from BioLog. W-13 (Calmodulin antagonist) was purchased from Calbiochem. All other reagents were purchased from Sigma. The affinity-purified PDE1A-specific rabbit polyclonal antibody was produced in Dr. Beavo's laboratory at the University of Washington 1 . We obtained similar results using a different rabbit polyclonal PDE1A peptide antibodies against peptide sequence (C)YAPDYSLSAVDLKS (aa470-483 of mouse PDE1A1). The affinity-purified rabbit polyclonal PDE1B antibody was generously provided by Dr. Beavo. We obtained similar results using an affinity-purified rabbit polyclonal PDE1B peptide antibody against peptide sequence: (C)PSLDVDVGDPNPDV (aa464-477 of mouse PDE1B1). The purified mouse monoclonal PDE1C antibody (114C) was provided by ICOS. We obtained similar results using a an affinity-purified rabbit polyclonal PDE1C peptide antibody against peptide sequence (C)APINNSVIPVDYKS (aa492-505 of mouse PDE1C1) . PDE1A shRNA targeting the rat PDE1A (1519-1547nt) was designed and adenovirus expressing the PDE1A shRNA was generated as previously described 2 . PDE1A siRNA was purchased from Dharmacon and PDE1C siRNA was purchased from Ambion. At least two different siRNA duplexes were tested for each. Adenovirus expressing PKG I shRNA was generously provided Dr. Kukreja at the Virginia Commonwealth University 3 . An shRNA that targets green fluorescent protein (GFP) or LacZ was used as a negative control. Adenovirus expressing the highly selective endogenous PKA inhibitor, (PKI) was described previously 4 . Adenovirus expressing the LacZ gene was used as a negative control.
Animal Models. All animal procedures were performed in accordance with the National Institutes of Health (NIH) and University of Rochester institutional guidelines. Cardiac hypertrophy was induced in vivo by chronic infusion of angiotensin II (Ang II) for 2 weeks or isoproterenol (ISO) for 1 week, as previously described 5 . Ang II was delivered at 0.7 mg/kg/day via subcutaneously implanted osmotic minipumps (Alzet) in 200-225 g Sprague-Dawley rats, while ISO was administered at 30 mg/kg/day in 10 week-old C57Bl/6J mice. Control animals received an infusion of vehicle alone. Thoracic aortic constriction (TAC) was performed in 8-10 week old male C57Bl/6J mice as previously described 5 . Aortic constriction was created via a left thoracotomy by placing a ligature securely around the ascending aorta and a 27-gauge needle and then removing the needle as described previously 6 . A similar sham operation was performed in control animals without constriction. IC86340 (3 mg/kg/day) or vehicle was administered once daily via intraperitoneal injection for 72 hours prior to implantation of ISO (30 mg/kg/d) or vehicle filled osmotic minipumps. IC86340 suspension was freshly prepared daily in 20% DMSO/buffered saline for animal experiments. The control group received daily injections consisting of the same volume of vehicle alone. Upon sacrifice, hearts and tibias were dissected and used to compare HW/BW (mg/g) and HW/TL (mg/mm) ratios in IC86340 and vehicle treated mice.
Hemodynamic measurements. A non-invasive tail-cuff plethysmography method (BP-2000; Visitech Systems) was used to monitor changes in systolic blood pressure and heart rate. Blood pressure and heart rate were recorded for 7 consecutive days prior to administering IC86340 for the training protocol and subsequently recorded daily for 1 week after ISO infusion. Both the training and actual recordings consisted of 10 preliminary measurements and 20 actual measurements per animal, of which a minimum of 60% successful measurements were included.
Blood plasma IC86340 bioassay. Blood plasma levels of IC86340 achieved in the in vivo experiments were determined upon collection of serial blood samples from IC86340 (or vehicle) i.p. injected mice. Blood samples (≥100 µl) were collected from submandibular and/or lateral saphenous veins at various timepoints (0, 1, 2, 4, 6, 8, 12, 16, and 24 hours) post injection. Plasma was separated by centrifugation and used in PDE assay against GST-purified recombinant PDE1A or PDE1C protein. An inhibitory curve of IC86340 was used to estimate the plasma concentration (approximately 12 µmol/L) from the timepoint of maximum PDE1 inhibition. These results demonstrate that the plasma levels of IC86340 were within both an effective and selective range to achieve PDE1 inhibition.
Histological and immunohistochemistry analysis. Excised mouse hearts were washed, fixed in 10% buffered formalin, and paraffin embedded as previously described 2 . Hearts were transversely sectioned (5µm), deparaffinized and stained for H&E for histopathology. Sections were subjected to heat-induced epitope retrieval (HIER) in a 10 mmol/L citrate buffer, pH 6.0 and endogenous peroxidases were blocked in an aqueous solution of 0.3% hydrogen peroxide. Sections were incubated in a serum-free protein blocking solution (DAKO) prior to staining. Myocyte cross-sectional areas were visualized using a membrane staining FITC-conjugated WGA (Sigma) at 10µg/ml for 2 hours at room temperature. WGA-stained myocyte areas were calculated using NIH Image J software and averaged from 200 myocytes per section for each animal. For immuno-histochemistry analysis rodent hearts were deparaffinized and immunostained using polyclonal PDE1A antibodies as previously described 2 . As a specificity control, adjacent sections were pre-incubated with PDE1A (or PDE1B) blocking peptides for 2 hours prior to incubation with primary antibodies. As an additional control, heart sections were incubated with a rabbit IgG with the primary antibody omitted.
Neonatal rat ventricular myocyte (NRVM) culture and treatment.
Primary cultures of cardiomyocytes were prepared from 2-3 day old Sprague-Dawley rat pups as previously described 7 . Briefly, hearts were excised and ventricles separated and rinsed in Hank's balanced salt solution (HBSS) prior to digestion with multiple rounds of collagenase type II (Worthington) containing HBSS. Cells were collected by centrifugation, resuspended in Dulbecco's Modified Eagle Medium (DMEM) containing 5% fetal bovine serum (FBS), 5% horse serum, 100 IU/ml penicillin, 100 µg/ml streptomycin and non-myocytes were removed by preplating the cells at 37 C for 1 hour. Cells were then cultured in DMEM (described above) containing 10 µmol/liter cytosine arabinoside (Ara-C) for 24 hours on gelatinized plates before switching to serum-free DMEM medium containing 0.2X insulin-transferrin-selenium (ITS). Cardiomyocytes were pre-treated with IC86340 or vehicle, or transduced with Ad-GFP shRNA or Ad-PDE1A shRNA (100 MOI), followed by stimulation with hypertrophic agonists for 48 hrs.
Adult rat ventricular myocyte (ARVM) culture and treatment.
Primary cultures of adult rat cardiomyocytes were prepared from 200-250g male Sprague-Dawley rats as previously described 8 . Briefly, rats were anesthetized, hearts excised and placed in Krebs buffer and perfused and digested with endotoxin-free collagenase II (Worthington). This protocol typically yielded approximately 4×10 6 cells per heart, with ~85% surviving, rod-shaped Ca 2+ -tolerant cells. Myocytes were allowed to attach to 20 µg/ml laminin coated plates in Modified Eagle Medium (MEM) containing 2.5% FBS, 25mmol/L HEPES, 5 mmol/L taurine, 2mmol/L carnitine, 2mmol/L creatinine, 100 IU/ml penicillin, and 100 µg/ml streptomycin for 2 hrs before replacing with serum-free MEM containing 25mmol/L HEPES, 5 mmol/L taurine, 2mmol/L carnitine, 2mmol/L creatinine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Myocytes were pre-treated with IC86340 or vehicle, or transduced with Ad-GFP shRNA or Ad-PDE1A shRNA (100 MOI) and stimulated with agonists for 24 hrs.
Human heart tissues. Explants from non-failing human myocardium were obtained from donors who had normal cardiac function (as assessed by echocardiography) and had not been prescribed cardiovascular medications, as previously described 5 .
RNA isolation and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR).
RNA was isolated from frozen human, rat, and mouse heart tissues using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Semi-quantitative RT-PCR was performed with an iCycler 4 thermocycler (Bio-Rad) by first synthesizing cDNA using oligo(dT) primers with the Reverse Transcription PCR kit (Promega) followed by standard PCR using GoTaq (Promega) according to the manufacturer's instructions. Human, rat, and mouse PDE1A, PDE1B, and PDE1C mRNA were measured using the following primer pairs: PDE1A: 5'-CTAAAGATGAACTGGAGGGATCTTCGGAAC-3' (Forward) and Quantitative real-time RT-PCR. Total RNA was extracted from frozen mouse tissue using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions and synthesized cDNA using oligo(dT) primers with the SuperScript First Strand Synthesis for RT-PCR kit (Invitrogen) according to the manufacturer's instructions. PCR amplications were quantified using SYBR Green PCR Master Mix (Applied Biosystems) and normalized to GAPDH mRNA expression.
Ca
2+ /CaM-dependent and independent PDE assay. PDE assays were performed using the established radiolabeled nucleotide method 9 . PDE1A and PDE5A activities were measured using 1µmol/L 3 H-cGMP substrate in the presence of either 1 mmol/L of EGTA (Ca 2+ /CaMindependent PDE assay) or 4 µg/ml calmodulin and 0.8 mmol/L CaCl 2 (Ca 2+ /CaM-dependent PDE assay), as previously described 10 . Briefly, PDE assay reactions were assembled on ice until initiation by adding radiolabeled nucleotide substrate. Reactions were incubated at 30ºC for 15 minutes and terminated at 95ºC for 1 minute. After cooling, 2.5 mg/ml snake venom (containing 5'-nucleotidase activity) was added to the reaction and incubated for 10 minutes at 30ºC. Assays were diluted with low salt solution and transferred to pre-equilibrated ionic exchange resin columns. The radiolabeled nucleoside was eluted from the resin with low salt solution and measured on a liquid scintillation counter. Total enzyme activity (% total minus background) was controlled in a linear range prior to each experiment.
Western blotting. Ventricular and myocyte lysates were prepared in a modified RIPA buffer containing the following: 50 mmol/L Tris-HCl pH 7.4, 1% NP-40, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L PMSF, 1 mmol/L sodium orthovanadate, 1 mmol/L NaF, and 1µ/ml each of aprotinin, leupeptin, and pepstatin as previously described 5 . Total protein lysates were separated using SDS-PAGE, transferred to a PVDF membrane and immunodetected with an affinity purified PDE1A rabbit polyclonal antibody, PDE1B rabbit polyclonal antibody, PDE1C mouse monoclonal or rabbit polyclonal antibody, PKG I rabbit polyclonal antibody (Assay Designs/Stressgen), or GAPDH mouse monoclonal antibody (Chemicon). Blots were quantified using Quantity One software (Bio-Rad).
Small Interfering RNA Transfection. PDE1A and PDE1C were silenced using a small interfering RNA (siRNA) duplex targeting rat PDE1A: UGUCAACGUUGUCGACCUA (Dharmacon) or rat PDE1C: UCCCGUCUUAUAAAGGAGG (Ambion). Freshly prepared NRVMs were transfected with the PDE1A or PDE1C siRNA duplexes using a Gene Pulser Xcell Electroporation system (Bio-Rad) according to the manufacturer's instructions. Briefly, 2x10 6 NRVMs were transfected with 1 µg of PDE1A siRNA or non-targeting control siRNA (Dharmacon) in 100 µl of siRNA electroporation buffer. Electroporated cells were allowed to recover for 24 hours in complete medium before replacing with serum-free medium. Alternatively, cardiomyocytes were transfected using Oligofectamine reagent (Invitrogen) in serum-free medium according to the manufacturer's instructions. Precipitates were washed twice with cold 95% ethanol, solubilized in 0.5 N NaOH for 30 min, and neutralized with 1N HCl. Radioactivity was quantified using a liquid scintillation counter. Each well was normalized to the total DNA content measured at 260 nm using an Eppendorf Biophotometer.
Cell size measurement. For morphometric analysis, NRVMs were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton-X 100, and immunostained with the myocyte marker, sarcomeric α-actinin antibody (Sigma). Fluorescent images were taken at 40X magnification using an Olympus BX-51 fluorescent microscope. Total NRVM surface areas were calculated using NIH Image J software, and expressed as the average of 100 randomly selected cells per condition. Non-fixed ARVMs were imaged and measured using brightfield microscopy. Total surface areas, lengths and widths were calculated from a minimum of 200 ARVMs using NIH Image J software.
Immunocytochemistry. Immunostaining was performed as previously described 2 . Briefly, NRVMs were fixed in 4% paraformaldehyde and permeabilized in 0.2% Triton-X. Cells were coimmunostained for a-actinin (Sigma) and ANP, using a purified rabbit polyclonal antibody (Peninsula) followed by secondary antibodies (goat anti-mouse Alexa Fluor 488 or anti-rabbit Alexa 546 (Invitrogen)), respectively. Cells were visualized with an Olympus BX-51 microscope. As specificity controls, ANP primary antibody was omitted and rabbit IgG was incubated prior to secondary antibody incubation.
Cyclic nucleotide measurements. cAMP and cGMP measurements were determined using radioimmunoassay (RIA) as previously described 10 . Briefly, NRVM were rinsed with cold PBS and lysed in 0.1N HCl. Supernatants were vacuum dried using a speed-vac, resuspended in 0.05M sodium acetate and used directly in RIA according to manufacturer's instructions (Biomedical Technologies, Stoughton, MA).
PKG and PKA non-radioactive assays. PKG-I activity was assayed from NRVM lysates using a non-radioactive enzyme linked immunosorbent assay (CycLex-PKG assay kit, MBL, Woburn, MA) and quantified by spectrophotometry. PKA activity was assayed using a non-radioactive PepTag PKA substrate assay according to the manufacturer's instructions (Promega, Madison, WI) and quantified by densitometry. Both PKG and PKA activities were calculated by measuring the DT-2-inhibitable or PKI-inhibitable activities, respectively.
Statistical analysis.
Experiments were performed and quantified in a randomized manner using at least three independent preparations with treatments done in triplicate. Data is presented as mean±SD. GraphPad Prism 4.0 was used for statistical analysis. One-way or two-way analysis of variance (ANOVA) followed by Bonferonni's post-test was used to determine the statistical significance, as appropriate. Comparisons between two groups were performed using unpaired Student's t-test. P-values <0.05 were considered statistically significant. Systolic blood pressure and (B) heart rate recordings using non-invasive tail cuff plethysmography. 10-12 week old C57Bl/6J mice were treated with vehicle or IC86340 at 3 or 6 mg/kg/d via i.p. injection once daily for one week. Blood pressure and heart rate were measured for 7 consecutive days during the training protocol and subsequently recorded daily for 1 week after administering IC86340. Both the training and actual recordings consisted of 10 preliminary measurements and 20 actual measurements per animal, of which a minimum of 60% successful measurements were included. Data represent mean ± SEM (n=3-4 mice per group). We observed a slight reduction in systolic blood pressure after 4 days of administering IC86340. Also, heart rate was not significantly altered between the groups.
Supplemental Table
Together, these findings suggest that PDE1 inhibition may have limited effects on vascular reactivity and systemic blood pressure, but does not result in hypotension at the doses used in this study. #P<0.05 vs. ctrl + vehicle, *p<0.05 vs. PE + vehicle. We found that PE caused significant decrease of intracellular cGMP level. PDE1 inhibitor IC86340 blocked PE effects on cGMP and further increased the cGMP level. When Ca 2+ signaling was inhibited by BAPTA-AM/EGTA or W-13, PE effects on attenuation of cGMP were significantly blunted, and PDE1A inhibitor IC86340 was no longer able to increase cGMP. These observations indicate that PE effects on cGMP attenuation is mediated by PDE1A activation, which is Ca 2+ /CaM-dependent. Data were normalized to total DNA content and expressed relative to control (vehicle alone) that was arbitrarily set to 1.0. Values are mean ± SD from triplicates. Similar results were observed from three independent experiments. #p<0.05 vs. vehicle control, *p<0.05 vs. vehicle+PE, †p<0.05 vs. PE + IC86340 or PE + sildenafil. (B and C) The effects of sildenafil on PDE5A and PDE1A activity. PDE5A and PDE1A activities were measured by PDE assay as described under "Experimental Methods" using GST-PDE5A or GST-PDE1A recombinant protein.
The IC50 values are defined as the concentrations of sildenafil required to produce 50% inhibition. The sildenafil used in this study is prepared from drug tablets. The IC 50 values for PDE5A and PDE1A are 26 nM and 2.4 µM, respectively. Therefore, the concentrations of sildenafil (0.1 µM and 1 µM) used in this study should preferentially hydrolyze PDE5A. As shown in (A), inhibiting PDE1 with 15 µM IC86340 or inhibiting PDE5 with 1 µM sildenafil reduced PE-stimulated hypertrophy about 80% or 70%, respectively. When two inhibitors were used together, the PE-stimulated hypertrophy was further reduced to about 100%, indicating combined PDE1 and PDE5 inhibitors may elicit additive anti-hypertrophic effects in NRVM. These in vitro data further suggest that PDE1 and PDE5 may control different pools of cGMP, both of which may regulate common distal hypertrophic signaling. Therefore, inhibiting either one alone could produce a robust anti-hypertrophic effect. The anti-hypertrophic effect from PDE1 or PDE5 inhibition is nearly equivalent.
